Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients

Inclusion Criteria: * Age ≥18 and ≤75 years old * A diagnosis of cirrhosis based on liver biopsy or on the combination of clinical, laboratory and imaging criteria * Compensated Child-Pugh B7-C10 * Any of the following causal factors : past but controlled excessive alcohol intake (\<30g/d for men and \<20g/d for women), HCV infection without viral replication, HBV infection without viral replication on therapy, metabolic syndrome, biliary cirrhosis, auto-immune cirrhosis, hemochromatosis, cryptogenetic cirrhosis Exclusion Criteria: * Ascites, portal hypertensive bleeding or encephalopathy within the last 3 months prior to enrolment * Hepatocellular carcinoma non considered in remission * Budd Chiari syndrome non considered in remission * Liver transplantation * F2 or F3 varices without treatment in accordance with recommended guidelines (B-blockers, ligation or both) * Portal vein thrombosis * Transjugular intrahepatic portosystemic shunt * Known extra-hepatic malignancies * PT\<35% * Platelet count\<50,000/mm3 * Haemoglobin level \< 9g/dl * Serum Albumin \< 20g/L * A bone mineral density T score of less than -4.0 at the lumbar spine or total hip * Known HIV infection * Ongoing anticoagulation or antiaggregation * Renal insufficiency defined by creatinine clearance\<60ml/mn * Conditions at risk for spontaneous bleeding (except for portal hypertension) or hemostatic abnormalities not related to cirrhosis * Pregnancy or breast-feeding